Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 25.0% in December

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 35,100 shares, a decrease of 25.0% from the November 30th total of 46,800 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 46,100 shares, the days-to-cover ratio is currently 0.8 days.

Avenue Therapeutics Stock Up 4.3 %

NASDAQ:ATXI traded up $0.08 during mid-day trading on Friday, hitting $1.94. 32,429 shares of the stock traded hands, compared to its average volume of 56,841. The business’s 50-day moving average price is $2.00 and its 200 day moving average price is $2.55. The company has a market cap of $3.98 million, a PE ratio of 0.11 and a beta of -0.20. Avenue Therapeutics has a 12-month low of $1.60 and a 12-month high of $26.47.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC bought a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned 1.17% of Avenue Therapeutics at the end of the most recent reporting period. Institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.